Aduro BioTech, Inc. has entered into its second agreement with Janssen Biotech, Inc., granting an exclusive, worldwide license to certain product candidates for the treatment of lung cancer and certain other cancers, based on its LADD immunotherapy platform.   Aduro will receive $30 million upfront and is eligible to receive development, regulatory and commercialization milestones potentially totaling $817 million. Aduro is also eligible to receive royalties on worldwide sales upon commercializa...